Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.
You may also be interested in...
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Strong Sobi With New Asset: A Takeover Target For Sanofi?
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.